International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
Международная распространенность, выявление и лечение факторов сердечно-сосудистого риска у амбулаторных пациентов с атеротромбозом
2006-01-10
SCID: 54.1/fnr537p6
Discuss with AI
REACH Registryatherothrombosiscardiovascular risk factorsevidence-based therapiesrisk factor control
Figures from the paper
Abstract (AI)
CONTEXT: Atherothrombosis is the leading cause of cardiovascular morbidity and mortality around the globe. To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis. OBJECTIVE: To determine whether atherosclerosis risk factor prevalence and treatment would demonstrate comparable patterns in many countries around the world. DESIGN, SETTING, AND PARTICIPANTS: The Reduction of Atherothrombosis for Continued Health (REACH) Registry collected data on atherosclerosis risk factors and treatment. A total of 67,888 patients aged 45 years or older from 5473 physician practices in 44 countries had either established arterial disease (coronary artery disease [CAD], n = 40,258; cerebrovascular disease, n = 18,843; peripheral arterial disease, n = 8273) or 3 or more risk factors for atherothrombosis (n = 12,389) between 2003 and 2004. MAIN OUTCOME MEASURES: Baseline prevalence of atherosclerosis risk factors, medication use, and degree of risk factor control. RESULTS: Atherothrombotic patients throughout the world had similar risk factor profiles: a high proportion with hypertension (81.8%), hypercholesterolemia (72.4%), and diabetes (44.3%). The prevalence of overweight (39.8%), obesity (26.6%), and morbid obesity (3.6%) were similar in most geographic locales, but was highest in North America (overweight: 37.1%, obese: 36.5%, and morbidly obese: 5.8%; P<.001 vs other regions). Patients were generally undertreated with statins (69.4% overall; range: 56.4% for cerebrovascular disease to 76.2% for CAD), antiplatelet agents (78.6% overall; range: 53.9% for > or =3 risk factors to 85.6% for CAD), and other evidence-based risk reduction therapies. Current tobacco use in patients with established vascular disease was substantial (14.4%). Undertreated hypertension (50.0% with elevated blood pressure at baseline), undiagnosed hyperglycemia (4.9%), and impaired fasting glucose (36.5% in those not known to be diabetic) were common. Among those with symptomatic atherothrombosis, 15.9% had symptomatic polyvascular disease. CONCLUSION: This large, international, contemporary database shows that classic cardiovascular risk factors are consistent and common but are largely undertreated and undercontrolled in many regions of the world.
Key Findings
1
Evidence-based prevention was suboptimal: statin use was 69.4% overall, antiplatelet use was 78.6%, and half had elevated blood pressure at baseline.
2
Overweight, obesity, and morbid obesity were most prevalent in North America, including obesity at 36.5% and morbid obesity at 5.8%.
3
Residual risk remained substantial, with 14.4% of patients with established vascular disease currently smoking, 4.9% having undiagnosed hyperglycemia, and 36.5% impaired fasting glucose.
4
The REACH Registry analyzed 67,888 outpatients from 44 countries with established atherothrombosis or at least three major risk factors.
5
Worldwide, patients showed similarly high prevalence of hypertension (81.8%), hypercholesterolemia (72.4%), and diabetes (44.3%).
Research Object
Outpatients with established atherothrombotic arterial disease or at least three atherothrombosis risk factors across 44 countries
Research Subject
International prevalence, recognition, treatment intensity, and control of atherosclerosis risk factors
Publication Details
Publication Date
2006-01-10
Journal
Publisher
ISSN
Cited by
1653
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by6
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
2018 ESC/ESH Guidelines for the management of arterial hypertension2018
2013 ESH/ESC Guidelines for the management of arterial hypertension2013
European guidelines on cardiovascular disease prevention in clinical practice: executive summary2007
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023
Epidemiology of Peripheral Artery Disease2015